SCHOLAR ROCK HOLDING CORP
SRRKNASDAQTrading Snapshot
- Day Range
- $756.59 – $766.16
- 52-Week Range
- $27.07 – $61.76
- Volume
- $2.93B
- Avg Volume
- $2.62B
- Shares Outstanding
- 119.8M
- Next Earnings
- Nov 16, 2026
Fundamentals Snapshot
- Annual Revenue
- $47M
- Last Q Revenue
- $13M
- P/E Ratio
- —
- P/S Ratio
- 125.2x
- EPS (TTM)
- $-3.30
- Dividend Yield
- —
- Dilution (1yr)
- +14.9%
Why Investors Own SRRK
- ✓High-growth profile — revenue up +25.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 29% gross margin and 21% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
SCHOLAR ROCK HOLDING CORP
SRRK
StockOtter · stockotter.spaceAbout SCHOLAR ROCK HOLDING CORP
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
SCHOLAR ROCK HOLDING CORP tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift SRRK price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
SCHOLAR ROCK HOLDING CORP announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.